Activates TLR3, induces the production of type I interferon and other cytokines, enhances antigen-specific CD8+ T-cell response, improves vaccine immunity, and enhances the anti-tumor effect of NK cells. Used in influenza, HIV, Zika virus, SARS-CoV-2 and other viral vaccine and tumor immunotherapy studies. Here, CD8A is linked to influenza.